Cystatin C as a new biomarker of renal dysfunction in HIV-1 infected patients ?preliminary report

详细信息    查看全文

• 作者：Robert Kranc ; Magdalena Monika D?browska ; Alicja Wiercinska-Drapa?o ; ^{awiercinska@gmail.com} ; Robert Flisiak
• 关键词：HIV-1 infection ; ARV therapy ; renal dysfunction ; cystatin C ; biomarker
• 刊名：HIV & AIDS Review
• 出版年：2008
• 出版时间：2008
• 年：2008
• 卷：7
• 期：1
• 页码：22-25
• 全文大小：100 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Background

HIV-1 infection and ARV therapy can cause progressive renal dysfunction. The aim of our study was to evaluate serum cystatine C (Cys-C) concentration and their possible relationships with the degree of renal injury in HIV-1 infected patients with or without antiretroviral therapy.

Material and Methods

Study was performed in 34 HIV(+) and 17 HIV(-) individuals. In 20 already treated HIV(+) Cys-C concentration was measured once; in the rest: before, after 3 and 9 months of HAART. Serum Cys-C concentration was measured by ELISA. Plasma urea and creatinine levels were measured. Creatine clearance was calculated by Cockroft-Gault formula.

Results

Serum Cys-C concentration in untreated and treated HIV(+) patients was significantly higher than in control group (441.94 ¡À121.62 and 513.10 ¡À94.12 v. 309.9 ¡À49.4 ng/ml, p < 0.001, respectively). After 3 months of HAART Cys-C concentration decreased to 379.74 ¡À42.15 ng/mL, and after 9 months increased to 384.52 ¡À41.23 ng/mL. Conclusion. Cys-C serum concentration is elevated in HIV-1-infected patients. Its decrease during the initial phase of ARV treatment suggests possible association with HIV viremia. HAART is associated with progressive increase of serum Cys-C concentration.